Safety, immunogenicity and evidence of effect of vaccine candidate CIGB-247 in the treatment of hepatocellular carcinoma.

Trial Profile

Safety, immunogenicity and evidence of effect of vaccine candidate CIGB-247 in the treatment of hepatocellular carcinoma.

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs CIGB 247 (Primary) ; Aluminium phosphate
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms CENTAURO-6
  • Most Recent Events

    • 08 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top